?dysfunctional? approach to Covid-19 vaccine distribution
... He said the vaccines likely to reach the market a bit after the initial shots could have advantages. While Pfizer and Moderna have been the first companies to report early, encouraging results in late-stage clinical trials of their mRNA vaccines, Gates said the levels of antibodies elicited are much higher in more conventional vaccines being developed by Novavax and Johnson & Johnson; AstraZeneca?s comes in a little below the mRNA ones. Gates also said the cold-chain requirements and the cost of scaling up mRNA vaccine production ?is not as attractive? as the other approaches.
?The fact that Novavax and J&J are above Pfizer makes us very hopeful that in the first quarter [of 2021] those vaccines will get approved and those we can make in many hundreds of millions per month in these developing world factories.?...
dieser Satz " Daten für Impfstoffkandidaten von Johnson & Johnson und Novavax Inc. werden in den kommenden Monaten erwartet. " wie lange wird es denn nun noch dauern , da ist ja Biontech und Pfizer schon stark am Produzieren nicht so gut für unsere Aktie
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate
Analysis of safety and immunogenicity of the Novavax SARS-CoV-2-3Q-2P-FL immunogen in mice and baboons revealed strong B and T cell responses to the vaccine with no evidence of vaccine-associated enhanced respiratory disease (15). Phase 1 and 2 clinical trial results showed that the vaccine induced immune responses exceeding levels seen in COVID-19 patients (31). Overall, we found that NVAX-CoV2372 is stable, homogeneous, and locked in the antigenically preferred prefusion conformation. With structural, biophysical, and antigenic characterization now complete, ongoing evaluation in humans will provide the true proof-of-principle for this vaccine concept.